乙型肝炎表面抗原量化对慢性乙型肝炎患者实现功能治愈的影响:系统性审查和元分析
Shun Li1, Lichen Shi2, Cheng Huang2
1National Clinical Research Center for Digestive Diseases, State Key Lab of Digestive Health, Beijing Friendship Hospital, Capital Medical University, Beijing, China; Clinical Epidemiology and EBM Unit, Beijing Clinical Research Institute, Beijing, China.
Annals of hepatology
|May 2, 2025
概括
确定最佳基线乙型肝炎表面抗原 (HBsAg) 水平可以预测功能治愈. 在慢性乙型肝炎患者中,500-1000 IU/mL的值表明治疗反应率更高.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
背景情况:
- 基线B型肝炎表面抗原 (HBsAg) 水平对于预测功能治愈至关重要.
- 预测HBsAg损失的最佳HBsAg切断值仍未得到充分研究.
研究的目的:
- 系统地评估基线HBsAg水平对慢性乙型肝炎 (CHB) 患者实现功能治愈的影响.
- 为了确定最佳的HBsAg值来预测HBsAg损失.
主要方法:
- 24项涉及3446名参与者的研究的系统审查和元分析.
- 在PubMed,Embase和Cochrane图书馆搜索到2023年12月31日.
- 根据基线HBsAg水平和临床特征分层的HBsAg损失的聚合比例.
主要成果:
- 在组合治疗组中,观察到基线HBsAg<500-1000 IU/mL的最高HBsAg损失比例 (14-17%).
- 一年间的干扰素-核胺类比 (IFN-NAs) 组合治疗产生了比六个月 (1%) 的更高的HBsAg损失 (9%).
- 与高ALT (4%) 患者相比,正常ALT患者的HBsAg损失较高 (11%) .
结论:
- 预测功能治愈的最佳基线HBsAg值为500-1000 IU/mL.
- 这些值确定了对当前疗法的高响应亚群.
- 根据这些发现,进一步的研究可以改进治疗策略.
相关概念视频
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...